Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 8/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.38 |
| ▸ | LPL | P06858 | 1/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.35 |
| ▸ | UGCG | Q16739 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18070546 | 0.79 | UGCG (0.42) | PGRPDK2UGCGMAP4K4 | |
| SCHEMBL19862047 | 0.76 | UGCG (0.45) | PDK2UGCGNPC1RAB9AMEN1 | |
| SCHEMBL21122857 | 0.71 | PGR (0.42) | PGRPDK2LPLLIPGNPC1 | |
| SCHEMBL19862027 | 0.68 | CYP3A4 (0.40) | PGRUGCGNPC1RAB9AHTT | |
| SCHEMBL12937076 | 0.67 | PDK2 (0.54) | PGRPDK2 | |
| SCHEMBL12937062 | 0.67 | PDK2 (0.54) | PGRPDK2 | |
| SCHEMBL19862020 | 0.67 | UGCG (0.35) | PGRUGCGNPC1RAB9AMEN1 | |
| SCHEMBL13750433 | 0.65 | PDK2 (0.60) | PGRPDK2 | |
| SCHEMBL10025089 | 0.65 | PDK2 (0.42) | PGRPDK2LPLLIPGNPC1 | |
| SCHEMBL19862033 | 0.64 | CYP3A4 (0.40) | PGRUGCGMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759769-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARMECEUTICAL INC (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190248754-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMECEUTICAL INC (US) | 2019-08-15 | — | — | US | disclosed |
| US-10227312-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180044302-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2018-02-15 | — | — | US | disclosed |
| US-20180044302-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759769-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | GBA1, UGCG, GBA2 | PGR 3772/4885PDK2 1539/4885LPL 126/4885 |
| US-20180044302-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | GBA1, UGCG, GBA2 | PGR 3772/4885PDK2 1539/4885LPL 126/4885 |
| US-20190248754-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | GBA1, UGCG, GBA2 | PGR 3772/4885PDK2 1539/4885LPL 126/4885 |
| US-10227312-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | GBA1, UGCG, GBA2 | PGR 3772/4885PDK2 1539/4885LPL 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.